[go: up one dir, main page]

MX9708340A - Mejoras en la profilaxis del cancer de mama, o relacionadas con esta. - Google Patents

Mejoras en la profilaxis del cancer de mama, o relacionadas con esta.

Info

Publication number
MX9708340A
MX9708340A MX9708340A MX9708340A MX9708340A MX 9708340 A MX9708340 A MX 9708340A MX 9708340 A MX9708340 A MX 9708340A MX 9708340 A MX9708340 A MX 9708340A MX 9708340 A MX9708340 A MX 9708340A
Authority
MX
Mexico
Prior art keywords
breast cancer
methods
preventing breast
formula
preventing
Prior art date
Application number
MX9708340A
Other languages
English (en)
Other versions
MXPA97008340A (es
Inventor
Fredric Jay Cohen
Joan Ellen Glusman
Ronald Keith Knickerbocker
Nikolaus Thomas Nickelsen
Teri Janine Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9708340(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9708340A publication Critical patent/MX9708340A/es
Publication of MXPA97008340A publication Critical patent/MXPA97008340A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

La profilaxis del cáncer de mama a una mujer postmenopáusica, administrando a dicha mujer raloxifeno, o una de sus sales farmacéuticamente aceptables, en una cantidad de aproximadamente 30 a aproximadamente 150 mg por día.
MXPA/A/1997/008340A 1996-10-30 1997-10-29 Mejoras en la profilaxis del cancer de mama, o relacionadas con esta MXPA97008340A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
US60/029,850 1996-10-30
GB9624800.0 1996-11-29
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10
US60/040,260 1997-03-10

Publications (2)

Publication Number Publication Date
MX9708340A true MX9708340A (es) 1998-08-30
MXPA97008340A MXPA97008340A (es) 1998-11-12

Family

ID=

Also Published As

Publication number Publication date
NL1007387C2 (nl) 1998-05-14
TR199900951T2 (xx) 1999-07-21
CN1182590A (zh) 1998-05-27
ITMI972434A1 (it) 1999-04-29
IL122025A0 (en) 1998-03-10
NO974972L (no) 1998-05-04
EE03663B1 (et) 2002-04-15
ATE239475T1 (de) 2003-05-15
GR970100409A (el) 1998-06-30
GB2318733A (en) 1998-05-06
FR2755014A1 (fr) 1998-04-30
EP1369115B1 (en) 2006-09-06
CZ341297A3 (cs) 1998-05-13
AR010538A1 (es) 2000-06-28
JPH10147530A (ja) 1998-06-02
BG103369A (en) 2000-05-31
NL1007386C2 (nl) 1998-05-14
IL122026A0 (en) 1998-03-10
NO974972D0 (no) 1997-10-28
CA2219070A1 (en) 1998-04-30
IE970773A1 (en) 2000-02-09
PT839532E (pt) 2003-09-30
AU731388B2 (en) 2001-03-29
AP971A (en) 2001-05-30
HUP9701778A3 (en) 1999-06-28
SI0839532T1 (en) 2003-10-31
GB9722796D0 (en) 1997-12-24
SK55999A3 (en) 2000-06-12
RO120813B1 (ro) 2006-08-30
EE9900162A (et) 1999-12-15
DK1369115T3 (da) 2007-01-02
GR1003189B (el) 1999-09-01
IL122025A (en) 2003-01-12
GR970100408A (el) 1998-06-30
EP0839533A1 (en) 1998-05-06
LV12353A (lv) 1999-10-20
ES2271476T3 (es) 2007-04-16
AU4364797A (en) 1998-05-07
EA200100716A1 (ru) 2002-06-27
HUP9701777A3 (en) 1999-07-28
MY121623A (en) 2006-02-28
NO322468B1 (no) 2006-10-09
CA2219070C (en) 2007-12-18
DK0839532T3 (da) 2003-08-25
YU42397A (sh) 2000-10-30
ES2197312T3 (es) 2004-01-01
DE69721692T2 (de) 2004-03-25
CH691847A5 (fr) 2001-11-15
IT1298470B1 (it) 2000-01-10
EA006083B1 (ru) 2005-08-25
HUP9701777A2 (hu) 1999-06-28
EP1369115A1 (en) 2003-12-10
ES2135343A1 (es) 1999-10-16
HU9701777D0 (en) 1997-12-29
HU9701778D0 (en) 1997-12-29
BG63841B1 (bg) 2003-03-31
GB2318734B (en) 1999-12-01
JPH10147529A (ja) 1998-06-02
GB2318734A (en) 1998-05-06
ITMI972433A1 (it) 1999-04-29
GEP20032910B (en) 2003-03-25
IE970772A1 (en) 2000-02-09
SK287047B6 (sk) 2009-10-07
SG72765A1 (en) 2000-05-23
US6303634B1 (en) 2001-10-16
ES2135342A1 (es) 1999-10-16
BE1011381A5 (fr) 1999-08-03
CZ300261B6 (cs) 2009-04-01
ATE338551T1 (de) 2006-09-15
IS5035A (is) 1999-04-27
CN1182591A (zh) 1998-05-27
AU5005697A (en) 1998-05-22
LU90158B1 (fr) 1998-06-02
EA199900431A1 (ru) 1999-10-28
BE1011382A5 (fr) 1999-08-03
NO974973D0 (no) 1997-10-28
AR013864A1 (es) 2001-01-31
WO1998018325A1 (en) 1998-05-07
LV12353B (en) 2000-02-20
SI1369115T1 (sl) 2006-12-31
DE69736644D1 (de) 2006-10-19
HUP9701778A2 (hu) 1999-01-28
DE69736644T2 (de) 2007-10-25
CH693820A5 (fr) 2004-02-27
MX9708341A (es) 1998-08-30
EA002054B1 (ru) 2001-12-24
FR2756490A1 (fr) 1998-06-05
CZ341197A3 (cs) 1998-05-13
PT1369115E (pt) 2006-12-29
SI20107A (sl) 2000-06-30
GB9911557D0 (en) 1999-07-21
UA46762C2 (uk) 2002-06-17
SG83672A1 (en) 2001-10-16
ES2135342B1 (es) 2000-05-16
BR9712703A (pt) 1999-10-26
US20020019418A1 (en) 2002-02-14
AU5005197A (en) 1998-05-22
FR2756490B1 (fr) 2003-06-20
HK1010495A1 (en) 1999-06-25
CA2219377A1 (en) 1998-04-30
WO1998018449A1 (en) 1998-05-07
EP0839532A1 (en) 1998-05-06
EP0839532B1 (en) 2003-05-07
LU90157B1 (fr) 1998-06-02
AU4364897A (en) 1998-05-07
AP9901494A0 (en) 1999-03-31
NZ329042A (en) 1999-08-30
GB9722801D0 (en) 1997-12-24
DE69721692D1 (de) 2003-06-12
FR2755014B1 (fr) 1999-02-05

Similar Documents

Publication Publication Date Title
MY121623A (en) Methods of preventing breast cancer.
MY119403A (en) Novel compounds with analgesic effect.
GB8804164D0 (en) Bandage for administering physiologically active compound
ZA977087B (en) Methods of cancer treatment using naaladase inhibitors
BG106104A (en) Method for the treatment of diseases related to increased number of neutrophils or neutrophil overactivation
IL127605A0 (en) Methods of cancer treatment using naaladase inhibitors
FI934680A0 (fi) Arylmorfolin, framstaellning och anvaending
GEP20043157B (en) Medicament Against Migraine Recurrence
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
CZ223199A3 (cs) Použití inhibitorů COMT nebo jejich farmaceuticky vhodných solí nebo esterů pro výrobu léčiva k prevenci diabetických vaskulárních dysfunkcí
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
SI0711163T1 (en) Use of benzydamine in the treatment of pathological conditions caused by tnf
IL126158A0 (en) Method for treating substance abuse
WO2000010590A3 (en) Cancer treatment
MY118982A (en) Method of reducing tissue damage associated with ischemia
IL115023A0 (en) Methods of reducing scarring in wound healing
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.
MX9707735A (es) Nuevo uso de (s)-adenosil-l-metionina (same).
IL152080A0 (en) Use of raloxifene or pharmaceutically acceptable salts or solvates thereof, in the preparation of a medicament for preventing breast cancer
MY103748A (en) A new antitumor agent obtained by microbial stereoselective reduction of 4-deoxy-4-iododoxorubicin
NZ336321A (en) Use of benzothiophene (raloxifene) for treating breast cancer
MX9706759A (es) Uso de penciclovir para el tratamiento de virus deherpes 8 humano.
MX9804797A (es) Nuevos compuestos con efecto analgesico.

Legal Events

Date Code Title Description
FG Grant or registration